Xencor Cuts Losses, Advances Pipeline Despite Revenue Slide

Xencor (XNCR) reported Q4 2025 results showing significant cost discipline and progress in its therapeutic pipeline. While revenue fell sharply, the company exceeded adjusted EPS estimates and provided updated 2026 guidance. Xencor’s cash reserves remain robust, supporting operations through 2028, and its oncology programs advanced with key clinical milestones.

Revenue

The total revenue of Xencor declined by 46.5% to $28.24 million in 2025 Q4, down from $52.79 million in the prior-year period. This contraction reflects reduced royalty income from Ultomiris and ongoing challenges in commercializing its therapeutic candidates.

Earnings/Net Income

Xencor narrowed its net loss to $-6.65 million in 2025 Q4, representing an 85.6% reduction compared to the $-46.20 million loss in 2024 Q4. The adjusted EPS improved from a loss of $0.65 to $0.09 per share, a 85.7% improvement. This demonstrates effective cost management despite lower top-line revenue.

Price Action

The stock price of Xencor has edged down 0.99% during the latest trading day, has climbed 5.64% during the most recent full trading week, and has dropped 6.26% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Xencor (XNCR) shares after its revenue drop quarter-over-quarter on the financial report released date and holding for 30 days resulted in a significant underperformance. The strategy had a CAGR of -24.83% and an excess return of -124.48%, with a maximum drawdown of 81.59% and a Sharpe ratio of -0.48. This indicates that the strategy was not only unable to generate positive returns but also exposed investors to considerable risk.

CEO Commentary

Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor, highlighted progress in oncology and autoimmune pipelines, emphasizing XmAb819’s first-in-class T-cell engagement for ccRCC and expansion into CRC, NSCLC, and pRCC. He noted enthusiasm for dose-expansion data in 2H26 to support a Phase 3 dose recommendation, with a pivotal study planned for 2027. Xencor also advanced XmAb942 in UC (XENITH-UC trial) and initiated XmAb412, a novel TL1A x IL23p19 bispecific. Dahiyat expressed pride in the team’s execution and focus on designing proteins for novel therapies, underscoring optimism about 2026 clinical data presentations and pipeline progress.

Guidance

Xencor expects to end 2026 with $400–$430 million in cash, cash equivalents, and marketable securities, funding operations through 2028. The company anticipates presenting XmAb819’s dose-expansion data in 2H26 and initiating a pivotal study in 2027. Royalty revenue from Ultomiris via the Xtend Fc patent is projected to generate $100–$120 million through 2028. Financial results for 2025 showed $125.6 million revenue (up from 2024) and a net loss of $91.9 million, with R&D and G&A expenses rising to $239.4 million and $63.6 million, respectively.

Additional News

Xencor’s balance sheet remains a strategic advantage, with $610.8 million in cash and equivalents as of December 2025. Recent updates include Incyte’s EU approval of a Xencor-partnered lymphoma therapy and positive Phase 3 data in solid tumors. The company’s collaboration with Incyte continues to yield regulatory milestones, bolstering long-term value. Additionally, Seeking Alpha’s Quant Rating upgraded Xencor to a “Hold,” citing mixed earnings estimate revisions. Management’s focus on dose-expansion data and bispecific antibody development positions the firm for potential 2027 catalysts.